Cytotoxicity of Poly(Phenolic)Sulfonates and Their Sodium Salts in L1210 Lymphoid Leukemia Cells by Wang, Fei et al.
CYTOTOXlCITY OF POLY(PHENOLIC)SULFONATES AND THEIR
SODIUM SALTS IN L1210 LYMPHOID LEUKEMIA CELLS
Fei Wang, Amy E. Warren, Cheryl R. Barnes and Iris H. Hall*
Division of Medicinal Chemistry and Natural Products
University of North Carolina Chapel Hill, N.C. 27599-7360, USA
ABSTRACT
Poly(phenolic)-sulfonates demonstrated very good cytotoxicity against the growth of tumor cell lines
(L1210, Tmolt-3, HeLa-S3) and are comparable in potency with typical clinically used anticancer drugs.
Four of the most active compounds, i.e. GL-2021, GL-2029, GL-2041 and GL-2063, were selected for a
mode of action study in L1210 lymphoid leukemia cells at concentration of 25ktM to 100M for 60 min.
The agents did not alkylate bases of ct-DNA, cause intercalation between base pairs, produce cross linking
of ct-DNA strands or generate free radicals although L1210 DNA fragmentation was observed aider 24 hr
incubation. L1210 DNA synthesis was preferentially inhibited which was achieved by (1) suppressing DNA
polymerase ct activity which reduced the synthesis ofnew strands of DNA, (2) reducing of de novo purine
synthesis at the regulatory enzyme PRPP amido transferase which reduced d(GMP) levels, and (3)
inhibiting of nucleoside kinase activities which further reduced DNA synthesis. DNA template activity was
altered by the poly(phenolic)sulfonates since they reduced DNA polymerase ( and m-RNA and t-RNA
polymerase activities. The kinetic studies at 50 ktM over 2 hr demonstrated that the agents’ effect on
PRPP-amido transferase activity is probably a major target ofthe compounds.
INTRODUCTION
Large molecular weight polymers, e.g. sulfated polysaccharide dextran sulfate, pentosan polysulfate, have
demonstrated anti-HIV-1 and anti-HIV-2 activity by interfering with binding of the gp120 protein to CD4
and blocking reverse transcriptase activity 1]. Hepsulfam, a new antineoplastic alkanesulfonate agent, has
demonstrated a broad preclinical activity in human tumor xenografts [2,3] and oat cell lung cancer;
however, this agent exhibited in vitro toxicity in human bone marrow cells [3]. Suramin, a known
antitrypanosomal agent, was found to exert a strong inhibitory effect on RNA-directed DNA polymerase
(reverse transcriptase) activity of several oncornaviruses such as Moloney murine leukemia virus, murine
Rauscher leukemia viruses, Moloney murine sarcoma virus and avian myeloblastosis viruses [4-7].
Related to suramin is a class of sulfonic acid azo dyes, for example, Evans blue, which has been shown to
be active against replication of the AIDS virus [6]. Recently a series of poly(phenolic)sulfonated compounds
were shown to have potent anti-inflammatory activity and protection against induced endotoxic shock in
mice at 8 and 16 mg/kg, I.P [8]. These agents prove to be potent elastase and prostaglandin
cyclooxygenase inhibitors, blocking the release ofTNFt and IL-1 release. The binding of these cytokines
to high affinity receptors on their target cells were also competitively suppressed by the agents. These
compounds blocked the adhesion of leukocytes and macrophages to L929 fibroblasts grown in tissue
culture [5]. Because of these properties it was surmised that these poly(phenolic)sulfonated compounds may
have antineoplastic activity.
METHODS
Source of Compounds
Test compounds were supplied by GeneLabs, Inc. [Redwood City, CA [Table 1]. Radioisotopes were
obtained from New England Nuclear [Dupont, Boston, MA]. Substrates and co-factors were purchased om
Sigma Chemical Co., [St Louis, MO]. Pentosan sulfate and other antineoplastic standards were obtained
from Sigma Chemical Co. Tumor lines were obtained from American Type Culture Collection [Rockville,
MD].
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Table 1 Structures of Poly(phenolic)sulfonate Compounds
O2R"
n
Compound R’ R" n MW
#
G1-2041 H OH 8 1489.46
G1-2029 H OH 6 1117.09
G1-2030 H OH 4 744.73
GI-2021 CH3 ONa 8 1777.5
G1-2057 CH3 ONa 4 888.75
GI-2158 CH3 ONa 6 1333.13
GI-2063 OCH3 ONa 8 2001.65
G1-2042 OAc ONa 8 2017.73
Cytotoxicity
Poly(phenolic)sulfonates were tested for cytotoxic activity by homogenizing drug in 0.05% Tween 80/H20
to give a mg/ml stock concentration. These solutions were sterilized by passing them through an
acrodisc (45 I.tm). The following cell lines were maintained by literature techniques [9]: murine L1210
lymphoid leukemia, P-388 lymphocytic leukemia, rat UMR 106 osteosarcoma, human Tmolt3 acute
lymphoblastic T cell leukemia, HUT-8 lymphoma, HeLa-S suspended cervical carcinoma, HeLa solid
cervical carcinoma, KB epidermoid nasopharynx, A431 epidermoid carcinoma, colorectal adenocarcinoma
SW480, HCT-8 ileocecal adenocarcinoma, lung bronchogenic MB-9812, A549 lung carcinoma, and
glioma HS683. Geran et al.’s protocol [9] was used to assess the cytotoxicity of the compounds and
standards in each cell line. Cell numbers were determined by the trypan blue exclusion technique. Solid
tumor cytotoxicity was determined by Leibovitz et al. ’s method [10] utilizing crystal violeeOH and
read at 562 nm (Molecular Devices). Values for cytotoxicity were expressed as EDs0 g/ml, i.e. the
concentration of the compound inhibiting 50% of cell growth. A value of less than 4 g/ml was required
for significant activity ofgrowth inhibition.
Incorporation Studies
Incorporation of labeled precursors into 3H-DNA, 3H -RNA and 3H -protein for 10 L1210 cells was
obtained [11]. The concentration response for inhibition of DNA, RNA and protein synthesis of the
compounds at 25, 50 and 100 l.tM was determined for 60 min incubations. Incorporation of 14C -glycine
(53.0 mCi/mmol) into purines was obtained by the method of Cadman et al.[12]. Incorporation of 4C-
formate (53.0 mCi/mmol) into pyrimidines was determined by the method of Christopherson et al.[ 13].
Enzyme Assays
Inhibition of various enzyme activities was performed by first preparing the appropriate L1210 cell
homogenates or subcellular fractions, then adding the drug to be tested during the enzyme assay. For the
concentration response studies, inhibition of enzyme activity was determined at 25, 50 and 100 l.tM of
compounds G1-2021, G1-2029, GI-2041 and G1-2063 after 60 min incubations. DNA polymerase Ot
activity was determined in cytoplasmic extracts isolated by Eichler et aL’s method [14]. The DNA
polymerase assay was described by Sedwick et al.[15] using 3H-TTP. Messenger-, ribosomal- and
transfer-RNA polymerase enzymes were isolated with different concentrations of ammonium sulfate;
individual RNA polymerase activities were determined using 3H -UTP 16,17]. Ribonucleoside reductase
activity was measured using 4C -CDP with dithioerythritol [18]. The deoxyribonucleotides 4C -dCDP
were separated from the ribonucleotides by TLC on PEI plates. Thymidine, TMP and TDP kinase
activities were determined using 3H -thymidine (58.3 mCi/mmol) in the medium of Maley and Ochoa[19].
Carbamyl phosphate synthetase activity was determined with the method of Kalman et al. [20] and
citrulline was determined colorimetrically [21]. Aspartate transcarbamylase activity was measured using
the incubation medium of Kalman et al.[20], carbamyl aspartate was determined colorimetrically by the
method of Koritz et aL [22]. Thymidylate synthetase activity was analyzed by Kampf et al. ’s method [23].
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The 3H20 measured was proportional to the amount of TMP formed from 3H-dUMP. Dihydrofolate
reductase activity was determined by the spectrophotometric method of Ho et al.[24]. PRPP
amidotransferase activity was determined by Spassova et al. ’s method [25]. IMP dehydrogenase activity
was analyzed with 8-[14C]-IMP (54 mCi/mmol) (Amersham, Arlington Heights, IL) after separating XMP
on PEI plates (Fisher Scientific) by TLC [26]. Protein content was determined for the enzymatic assays by
the Lowry technique.
DNA Studies
After deoxyribonucleoside triphosphates were extracted [27], pool levels were determined by the method of
Hunting and Henderson [28] with calfthymus DNA, E. coli DNA polymerase I, non-limiting amounts of
the three deoxyribonucleoside triphosphates not being assayed, and either 0.4 mCi of (3H-methyl)-dTTP or
(5-3H)-dCTP. The effects of poly(phenolic)sulfonates on L1210 DNA strand scission was determined by
the methods of Suzuki et al.[29], Pera et al.[30], and Woynarowski et al.[31]. L1210 lymphoid leukemia
cells were incubated with 10 Ci thymidine methyl-3H, 84.0 Ci/mmol for 24 hr at 37C. L1210 cells
(107) were harvested and then centrifuged at 600 g X 10 min in PBS. They were later washed and
suspended in ml of PBS. Lysis buffer (0.5 ml; 0.5 M NaOH, 0.02 M EDTA, 0.01% Triton X-100 and
2.5% sucrose) was layered onto a 5-20% alkaline-sucrose gradient (5 ml; 0.3 M NaOH, 0.7 KC1 and 0.01
M EDTA); this was followed by 0.2 ml of the cell preparation. After the gradient was incubated for 2.5 hr
at room temperature, it was centrifuged at 12,000 rpm at 20C for 60 min (Beckman rotor SW60).
Fractions (0.2 ml) were collected from the bottom of the gradient, neutralized with 0.2 ml of 0.3 N HC1,
and measured for radioactivity. Thermal calf thymus DNA denaturation studies, U.V. absorption studies
and DNA viscosity studies were conducted after incubation of poly(phenolic)sulfonates 100 laM at 37C for
24 hr [32]. Free radical generation by the poly(phenolic)sulfonates from 25 laM to 100 laM incubated for
15 min at 37C with 106 LI210 lymphoid leukemia cells was determined with 0.25 mg/ml o-
phenanthroline, 0.1 mM EDTA and 0.1 mM ferric chloride in 20 mM phosphate buffer, pH 7.4 at 510 nm
[33]. Superoxide scavenger activity was determined in an analogous manner with 0.4 mM ferricytochrome
C in 20 mM phosphate buffer pH 7.4 at 37 C at 550 nm.[34]. Standards, i.e. 3% hydrogen peroxide and
zymosan at 5mg/ml [Sigma] were used to generate free radicals in the assays for comparison to the
poly(phenolic)sulfonates.
Statistical Test
In Tables 3-6, the data is represented as the average of the percent of control and the standard deviations.
In Fig 2-12, all standard deviations are within 5.2% of the value. The probable significant different [p]
between the treated raw data and the control raw data for each assay was determined using the Student’s
"t" test.
RESULTS
The poly(phenolic)sulfonates demonstrated potent cytotoxic activity [Table2] with EDso values of less than
4 t.tg/ml for significant activity. Mouse L1210 lymphocytic leukemia, human Tmolt3 T cell leukemia and
human HeLa-S uterine carcinoma growth were significantly reduced by all of the agents including the
standard pentosan sulfate with EDs0 values < 3 lag/ml. G1-2157 and G1-2021 demonstrated the best
activity in the L1210 lymphoid leukemia screen. G1-2063 was very potent in suppressing growth of
human Tmolt3 T cell leukemia cells. G1-2029 demonstrated the best activity against the growth of HeLa-S
uterine carcinoma. Human solid HeLa uterine carcinoma growth was significantly reduced by G1-2021 with
an EDs0 value of 1.97 lag/ml. KB nasopharynx growth was reduced by G1-2041 [EDs0 2.60 g/ml] and
moderately reduced by G1-2158 and G1-2063 with values of 3.24 and 3.42 lag/ml, respectively. Human
SW480 adenocarcinoma colon growth was significantly reduced by G1-2030, and GI-2021 with EDs0 values
less than 2 g/ml. Human lung MB9812 bronchogenic growth was suppressed moderately by G1-2063
and pentosan sulfate. Human HCT-8 ileum adenocarcinoma, lung A549, glioma HS683 and rat UMR-106
osteosarcoma growth was not affected by the test compounds.
Compounds G1-2021, G1-2029, G1-2041 and G1-2063 demonstrated the most potent activity in the mouse
L1210 lymphocytic leukemia screen and consequently were selected for the mode of action study. These
four agents preferentially affected L1210 lymphoid leukemia DNA synthesis with reduction of greater than
60% at 100 l.tM over 60 min [Tables 3-6]. RNA and protein syntheses were more moderately affected by
the agents with 13 -22% reduction ofRNA synthesis over 60 min at 100M and 29% to 43% reduction
of protein synthesis over hr. DNA polymerase x activity was reduced 33% to 56% after hr at 100
I.tM. m-RNA polymerase activity was reduced 50% to 60% and t-RNA polymerase activity was reduced
24% to 41% at 100 laM over hr. r-RNA polymerase activity was elevated slightly by G1-2021 20% to
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23% after hr from 25 to 100 ktM, but the other three agents had no significant effect on this enzyme
activity.
Table 3 Effects of GI-2021 on L1210 Leukemia Cell Metabolism over 60 Minutes
N=6 Percent of Control (X + SD)
Assay Control 25 laM 50 tM 100l.tM
DNA synthesis 100+5 105+6 77+5* 39+5*
RNA synthesis 100+6 109+6 94+6 78+4"
Protein synthesis 100+5 80+4" 64+4" 59+3 *
DNA polymerase c 100+64 76+5* 55+_4* 52+4*
mRNA polymerase 100+7 99+5 74+_4’ 40+_.4"
rRNA polymerase 100__.4 122+7 120+5 123+4
tRNA polymerase 100+7 98+5 85+5 76+4"
Ribonucleoside reductase 100+5 158+6" 124+5 91+5
Dihydrofolate reductase 100+5 97+._4 79+__4" 76+4’
Purine de novo synthesis 100+5 121+6 118+4 74+6"
PRPP amido transferase 100+6 62+5" 61+4" 39+__4"
IMP dehydrogenase 100+5 124+4 97+_.4 77+._4"
Pyrimidine de novo synthesis 100+5 98+6 94+__4 88+5
Carbamyl phosphate synthetase 100+7 94+5 89+5 62+__4"
Aspartate transcarbamylase 100+6 101+6 100+5 98+4
Thymidylate synthetase 100+5 97+6 88+5 82+4
Thymidine kinase 100+6 112+7 96+5 76+4"
Thymidine monophosphate kinase 100+7 110+6 35+__4" 32+3 *
Thymidine diphosphate kinase 100+6 32+._4" 32+3 * 26+3 *
d(ATP) 100+5 65+ 4
d(GTP) 100+6 79+4
d(CTP) 100+5 67+5
d(TTP) 100+4 88+6
Control values for 106 cells/hr
a DNA Synthesis 26152 dpm
b RNA Synthesis 4851 dpm
c Protein Synthesis 7461 dpm
d DNA polymerase t 47804 dpm
e m-RNA polymerase 1502 dpm
f r-RNA polymerase 4239 dpm
g t-RNA polymerase 6400 dpm
*P < 0.001 Student’s "t" test
Purine synthesis 92551 dpm
k PRPP-amido transferase =0.121 OD units
IMP dehyrogenase 19758 dpm
m Pyrimidine synthesis 76058 dpm
n Carbamyl phosphate synthetase 0.392 mol citrulline
o Asparate transcarbamylase 1.064 mol N-carbamyl aspartate
h Ribonucleoside reductase 2744 dpm p Thymidylate synthetase 18463 dpm
=Dihydrofolate reductase 0.868 OD units q Thymidine kinase 1317 dpm r Thymidine
monophosphate kinase 1179 dpm s Thymidine diphosphate kinase 1891 dpm
d[ATP] 6.17 pmol; u d[GTP] 5.27; pmol; v d [CTP] 6.87 pmol;w d[TTP] 6.94
pmol
Ribonucleoside reductase activity was not reduced by any ofthe four poly(phenolic)sulfonates over hr but
rather it was stimulated significantly particularly at the lower concentrations after this time period.
Dihydrofolate reductase activity was reduced only by compounds G1-2021 by 24% and G1- 2063 by 46%
at 100 t.tM after hr. L1210 de novo purine synthesis was suppressed 18% to 46% at 100 ktM of
poly(phenolic)sulfonates over hr with the activities ofregulatory enzyme PRPP amido transferase activity
being suppressed 61% to 90% and IMP dehydrogenase activity being reduced 23% to 34% at 100 tM
over hr. In all three of these assays the agents demonstrated a concentration dependent suppression of
activity. De novo pyrimidine synthesis was not significantly reduced by the agents at these concentrations
for hr. Carbamylate phosphate synthetase activity was reduced 27% to 38% at 100M after hr. But
aspartate transcarbamylase activity was not affected by the compounds, significantly. Thymidylate
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synthetase activity was reduced marginally 8% to 18% at 100 txM after hr. Thymidine kinase activity
was suppressed 12% to 24%, TMP kinase activity was reduced 63% to 68%, TDP kinase activity was
inhibited 46% to 74% after hr at 100 laM. Again, the effects of the agents on these latter two enzyme
activities was concentration dependent, d[NTP] pool levels were only marginally affected by the
compounds, d[ATP] levels were reduced 32% to 38% after hr at 100 M; whereas, d[GTP] pools were
reduced21% to 28% by the poly(phenolic)sulfonates, d[CTP] pool levels were lowered 4% to 33% and
d[TTP] levels 2% to 17% after hr incubation at 100 l,tM. ct-DNA studies demonstrated that the agents
did not affect DNA denaturation since the Tm values for the control was 82.8 C, G1-2021 was 81.5 C, G1-
2029 was 82.3 C, G1-2041 was 83 C and G1-2063 was 83C suggesting no cross linking of the strands of
DNA. ct-DNA U.V. absorption from 220 to 340 nm did not demonstrate a hyperchromic shift to a higher
wavelength [Fig. 1] suggesting that the agents did not interact with the individual bases of DNA, i.e.
alkylation of purines and pyrimidines.
Table 4 Effects of GI-2029 on L1210 Leukemia Cell Metabolism Over 60 min
N=6 Percent of Control (X+ SD)
Asa_v Control 25ttM 50.I,tM 100tM
DNA synthesis 100+5 83+_.4" 78+3" 37+__4"
RNA synthesis 100+6 91 +__6 91+5 79+__4"
Protein synthesis 100+5 82+._4 80+3" 71+3"
DNA polymerase o 100+6 70+3" 60+3" 44+3’
mRNA polymerase 100+7 72+_.4" 55+_4" 50+3 *
rRNA polymerase 100+4 115+6 102+4 107+5
tRNA polymerase 100+7 103+5 98+5 69+._4"
Ribonucleoside reductase 100+5 130+5’ 130+6" 141+5"
Dihydrofolate reductase 100+5 92+__4 108+5 127+6’
Purine de novo synthesis 100+5 130+6’ 97+6 72+._4"
PRPP amido transferase 100+6 36+__4* 30+3* 30+._2*
IMP dehydrogenase 100+5 270+5" 184+6" 74+._4"
Pyrimidine de novo synthesis 100+5 99+6 96+ 5 93+7
Carbamyl phosphate synthetase 100+7 78+5 * 74+._4" 72+3 *
Aspartate transcarbamylase 100+6 100+5 100+5 98+6
Thymidylate synthetase 100+5 92+5 89+6 87+_4
Thymidine kinase 100+6 105+6 104+6 76+_.4"
Thymidine monphosphate kinase 100+7 118+6 50+5* 32+._4"
Thymidine diphosphate kinase 100+6 57+3 * 50+_.4" 27+3 *
d[ATP] 100+5 68+5*
d[GTP] 100+6 72+.._4’
d[CTP] 100+5 96+ 5
d[TTP] 100+4 98+5
ct-DNA viscosity was unchanged after incubating with agents at 100 l,tM for 24 hr. The standard
chloroquine at 25 and 50 tM resulted in values of262-265 sec and acriflavine at 100 laM caused a value of
199.8 sec. and since all values, including the control, were between 217.3 and 218.6 sec., this suggests no
intercalation of the poly(phenolic)sulfonates between base pairs of DNA. L1210 DNA strand scission
studies after incubating 24 hr. at 100 tM [showed that DNA fragmentation occurred with smaller molecular
weight DNA in the higher fractions of the gradient [Fig 2]. DNA fragmentation was more evident with G1-
2021 and the effects were more moderated with G1-2029. Further study demonstrated that the L1210 DNA
fragmentation was not caused directly by free radical generation by the agents over 15 min as determined by
the Fenton reaction or the scavenger reaction [Fig 3 and 45].
Kinetic studies ofL1210 lymphocytic leukemia grown in the presence of agents at 25M [Fig.5] and 50
txM [data not shown] over 6 days showed that the agents were cytostatic rather than cytotoxic. The
concentrations employed for these studies were much higher than the concentrations for the EDso
values from the generated cytotoxicity study. If the EDs0 values for the cytotoxic assay were converted to
l,tM then G1-2021 would be 0.777 I,tM, G1-2029 would be 1.362 t,tM, G1-2041 would be 1.263 l.tM and
152Fei Wang, Amy E. Warren et al. Metal-Based Drugs
GI-2063 would be 1.36 tM. Nevertheless, mode of action studies are performed at higher concentrations,
which are usually multiples ofthe ED50 values, in order to identify the targets of the agents. L1210 DNA
synthesis over 2 hours in the presence of agents at 50 tM was reduced significantly after 60 min and
continued to be reduced in higher magnitude throughout the 2 hr. [Fig 6] following a time dependent
effect. DNA polymerase activity was reduced after 30 min with agents at 50 l.tM but with G1-2041 and
G1-2063 between 60 and 120 min the activity recovered.
Table 5 Effects of GI-2041 on L1210 Leukemia Cell Metabolism Over 60 Min.
N=6 Percent of Control (X+ SD)
Assay (0ntr01 25M 50IM 100.ttM
DNA synthesis 100+5 98+6 84+5 33+5
RNA synthesis 100+6 130+5 94+._4 86+._4
Protein synthesis 100+5 79+__4’ 70+3" 70+3"
DNA polymerase ot 100+6 85+5 77+_.4" 63+_.4"
mRNA polymerase 100+7 73+_4" 65+_4" 47+3 *
rRNA polymerase 100+4 112+5 102+_.4 93+._4
tRNA polymerase 100+7 108+6 66+...4" 60+._4"
Ribonucleoside reductase 100+5 127+5 127+6" 103+__4
Dihydrofolate reductase 100+5 105+5 97+._4 92+5
Purine de novo synthesis 100+5 85+5 68+_.4" 54+3"
PRPP amido transferase 100+6 38+_4" 38+3 * 10+2 *
IMP dehydrogenase 100+5 131+6" 79+__4" 70+4 *
Pyrimidine de novo stnthesis 100+5 112+6 97+5 95+__4
Carbonyl phosphate synthetase 100+8 142+6* 82+5 73+__4"
Aspartate transcarbamylase 100+6 106+5 97+__4 94+5
Thymidylate synthetase 100+5 105+5 103+6 92+5
Thymidine kinase 100+6 116+5 104+5 79+_.4’
Thymidine monophosphate kinase 100+7 80+5* 41+3* 36+__4"
Thymidine diphosphate kinase 100+6 89+5 64+5" 54+3 *
d[ATP] 100 62+ 5*
d[GTP] 100 74+5*
d[CTP] 100 89+_5
d[TTP] 100 89+6
With two of the compounds, i.e. GI-2021 and G1-2029, activity remained suppressed at 60 and 90 min.
[Fig 7] while with GI-2041 and G1-2063 the DNA polymerase activity returned to normal at 90 min.
L1210 m-RNA polymerase activity was significantly reduced after 30 min, but with increasing times of
incubation achieved the lowest value, e.g. 50% to 60% at 120 min. [Fig 8 ]. PRPP-amido transferase
activity was significantly reduced greater tha 60% aider 60 min and remained consistently suppressed over
the next 2 hr. [Fig 9]. Thymidine kinase activity was only marginally inhibited at 90 min and required
2 hr to observe at least 40% inhibition of activity [Fig 10]. TMP kinase activity demonstrated marked
reduction at 60 min but the activity recovered at 90 and 120 min [Fig 11 ]. TDP kinase activity was erratic
also with the highest reduction at 60 min but again the activity recovered after 90 min [Fig 12].
DISCUSSION
The poly(phenolic)sulfonates like many polymeric agents, e.g. suramin, demonstrated cytotoxic activity
against mouse, rat and human tumor cell lines with EDs0 values in the range of standard clinical agents.
These derivatives were very effective inhibitors in suspended mouse and human tumor cells, e.g. mouse
L1210 lymphoid leukemia, human Tmolt3 T cell leukemia, and HeLa-S uterine carcinoma. The
compounds were not as active against the growth of solid rat and human tumor cultured cells. Selective
activity was demonstrated by some ofthe agents. GI-2021 was effective against human solid HeLa uterine
carcinoma, GI-2041 was active against human KB nasopharynx carcinoma, GI-2158 was effective against
lung MB9812 bronchogenic carcinoma and GI-2030 and GI-2021 were active against growth of human
colon adenocarcinoma growth. The agents were not active against the growth of HCT-8 ileum
adenocarcinoma, lung A549, nor glioma HS683 growth.
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Table 6 The Effects of GI-2063. on L-1210 Nucleic Acid Metabolism After 60 min.
N=6 Percent of Control (X+ SD)
Assay Control 251aM 501aM 100M
DNA synthesis 100+5 128+7" 89+6" 39+__4"
RNA synthesis 100+6 94+5 87+...4 87+5
Protein synthesis 100+5 87+6 80+._4* 57+_4"
DNA polymerase a 100+6 97+5 94+__4 67+_4*
mRNA polymerase 100+7 129+5’ 71+5" 45+_4"
rRNA polymerase 100+4 87+__4 86+5 83+5
tRNA polymerase 100+7 100+5 70+3" 59+3"
Ribonucleoside reductase 100+5 128+5’ 120+5 112+6
Dihydrofolate reductase 100+5 81+6 81+5 54+3*
Purine de novo synthesis 100+5 95+5 85+6 58+_..4"
PRPP amido transferase 100+6 34+5* 29+3* 28+2*
IMP dehydrogenase 100+5 99+5 96+6 77+_4"
Pyrimidine de novo synthesis 100+5 103+6 102+5 98+5
Carbamyl phosphate synthesis 100+7 114+5 105+5 85+5
Aspartate transcarbamylase 100+6 96+_4 88+__4 79+3"
Thymidylate synthetase 100+5 89+__4 87+5 87+5
Thymidine kinase 100+6 123+5" 104+5 85+5
Thymidine monophosphate kinase 100+7 86+5 43+_4" 34+3"
Thymidine diphosphate kinase 100+6 100+6 37+__4" 29+3 *
d[ATP] 100+5 68+6*
d[GTP] 100+6 121+4"
d[CTP] 100__+5 69+5*
d[TTP] 100+_4 46+3’
Fig 1 The Effects of Poly(phenolic)suifonates on ct-DNA Absorption From 220 to 340 nm After 24
Hours Incubation at 100 tM
Optical
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Fig 2 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia DNA Strand Scission
at 100 tM Over 24 Hours
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The type of selectivity demonstrated by the poly(phenolic)sulfonates, was typical of antineoplastic agents
which interfere with cellular metabolism. Suramin has been shown to be an effective antineoplastic agent
against Kaposi’s sarcoma, non-Hodgkin lymphomas, lung carcinoma, metastatic prostate, adrenal
adenocarcinoma and kidney adenocarcinoma [35-37]. Kinetic growth studies demonstrated that the
poly(phenolic)sulfonate agents were cytostatic as opposed to cytocidal and they did not follow a
concentration dependent inhibition of growth of L1210 cells [from 25-50 M] at higher concentrations of
the agents. This could be due to saturation of cellular transport processes by the agent or saturation of the
key target receptor by the agent for inducing cell death. It is interesting to note that suramin, a hexasulfated
naphthylurea, required a concentration of 250 l.tg/ml or 1.75 mM in HeLa cells to cause death and required
40 laM to inhibit SV40 replication in HeLa cells [38]. The growth of human lung cancers PC-9, PC-14
and H69 and their resistant strains to cisplatin or etoposide was suppressed by suramin at 60 to 400
ktg/ml [39]. In Chinese hamster growth DC-3F and DC-3F/9-OH-E (resistant 9-hydroellipticine subline)
EDs0 values for suramin were 31 ktM and 203 ktM [41 ].
Fig 3 The Effects of Poly(phenolic)sulfonates on Free Radical Generation in LI210 Lymphoid
Leukemia at 25-100 ktM Over 15 Min
Percent Free Radical Fenton Reaction at 510nm
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Fig 4 The Effects of Poly(phenolic)sulfonates on Free Scavenger Generation in L1210 Lymphoid
Leukemia Cells at 25-100M for 15 Min.
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The poly(phenolic)sulfonates in the HeLa solid tumor screen afforded EDs0 values between 1.97 l.tg/ml and
8.74 ktg/ml and the A549 and MB98 lung tumor were suppressed between 3.49 gg/ml and 10.3 ktg/ml by
the agents suggesting that they probably would be more potent than suramin in vivo in suppressing cancer
growth. L1210 lymphoid leukemia mode of action studies with four of the more potent agents, i.e. G1-
2021, G1-2029, G1-2041, and G1-2063 from 25-100 ktM over 60 min demonstrated that DNA synthesis
appears to be the major target of the agents.That is not to exclude the moderate inhibition of protein
synthesis that occurred with some of the derivatives but certainly not by all four of the compounds. DNA
synthesis inhibition by the poly(phenolic)sulfonates is probably the result of multiple inhibitory effects of
the compounds which are additive to induce cell death. All four agents suppressed the activities ofDNA
polymerase ix, PRPP-amido tmnsfemse and TMP and TDP kinases significantly in a concentration
dependent manner. Moderate inhibition was observed by the agents for dihydrofolate reductase and IMP
dehydrogenase activities. The magnitude of inhibition of either one of these enzyme activities was not
sufficient to account for the observed reduction of DNA synthesis.Nevertheless, the summation of the
suppression of all ofthese metabolic events would be sufficient to account for the observed DNA synthesis
suppression in 60 min. The four agents generally followed a concentration dependent response for both the
inhibition ofDNA synthesis and suppression of the DNA polymerase tx, PRPP-amido transferase and TMP
and TDP kinases enzyme activities from 25-100 laM over 60 min. The four poly(phenolic)sulfonates
demonstrated similar IC50 values [75-84 l,tM] against LI210 DNA synthesis and for TMP-kinase inhibition
[40-50 tM]. It did not appear that a hydroxyl group or a sodium atom in the R" affected the inhibition
differently. In R’ group substitutions, hydrogens, methyl or methoxy groups appeared to make little
differences either. Nevertheless, all but one of the agents, i.e. GI-2021 demonstrated a very low IC50 value
for PRPP-amido transferase inhibition 17-19 I.tM]. There was no obvious reason for the difference in IC50
values ofthis enzyme for GI-2021 since the only difference between GI-2021 and G1-2063 is that the former
has a methyl group in R’ and G1-2063 has a methoxy group. The IC50 values [21-42 l.tM] for TDP kinase
inhibition were lower for the two compounds which were substituted in the R’ position with a methyl or
methoxy group.
Fig 5 The Effects of Poly(Phenolic)suifonates on Growth of LI210 Lymphoid Leukemia Cells at
251.tM for 6 Days
Percent L1210 Lymphoid Leukemia Growth at 251LtM Control
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Fig 6 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia DNA Synthesis at 50
t.tM over 2 Hours
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Fig 7 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia DNA polymerase
Activity at 50M Over 2 Hours
Percent
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The "n" number of the compound being 6 or 8 did not seem to explain the difference observed for the IC50
values for enzyme inhibition.
Fig 8 The Effects of Poly(phenolic)sulfonates on L1210 Lymphoid Leukemia m-RNA
polymerase Activity at 50 tM Over 2 Hours
Percent L1210 m-RNA polymerase Control
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Fig 9 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia PRPP-Amido
Transferase Activity Over 2 hours at 50[tM
Percent of
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The IC50 values [78-90 mM] for mRNA polymerase inhibition was slightly better with compounds
possessing an "n" of 8. The ability of the agents to suppress multiple enzymatic sites in nucleic acid
metabolism is not surprising since 6-MP, araC and 5-FU inhibit more than one metabolic process in cancer
cells. Inhibition ofDNA polymerase x activity by the agents would suppress the synthesis of a new strand
ofDNA in the S phase of the cell cycle. Ordinarily this would lead to the accumulation of d[NTP] pool
levels. However, this was not observed after the 60 min of this study, i.e. the d[NTP] remained
approximately normal or were slightly reduced in concentration. Since the poly(phenolic)sulfonates also
inhibited L1210 PRPP-amido transferase activity markedly from 25 to 100 l.tM over 60 min, this should
result in the reduction of over all de novo purine synthesis lowering the pool levels ofAMP and GMP.
These studies reflected the inhibition of purine synthesis in 60 min but the magnitude of reduction by the
agent was not as great as the inhibition ofPRPP-amido transferase activity at this time. This may be due
simply to a time delay in the effects of the agent and eventually the overall reduction of de novo purine
synthesis would be of the same magnitude of reduction as the suppression of the regulatory enzyme and
also the effects will be further reflected in the cellular d[NTP] pools.
Fig I0 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia Thymidine Kinase
Activity at 50 tM Over 2 Hours
Percent
Control
0,
L1210 Thymidine kinase
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Fig 11 The Effects of Poly(phenolic)sulfonates on LI210 Lymphoid Leukemia Thymidine
Monophosphate Kinase Activity at 50 txM Over 2 Hours
Percent
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Certainly even after 60 min the purine deoxyribonucleotides were generally reduced but the effects on
pyrimidine deoxyribonucleotides were not in evidence at this time of incubation. L1210 ribonucleoside
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reductase activity was not affected by the agents; thus, the conversion from ribonucleotides to
deoxyribonucleotides was not a factor in the mode of action ofthese agents.
Suramin in HeLa cells inhibited DNA synthesis with an IC50 value of 7 mM, DNA polymerase ct and
activities at 8 and 36 ktM, respectively non-competitively [40] and inhibited Rauscher leukemic virus,
Moloney murine sarcoma virus and avian myeloblastosis reverse transcriptase activities at concentrations
at 0.1 tg/ml 40, 7]. The viral studies suggest that suramin competes for the template binding site on
the enzyme [7]. Since L1210 RNA synthesis was marginally reduced by the poly(phenolic)sulfonates over
the 60 min period at 100 l.tM, this was probably the result of the reduction in ribonucleotides due to the
reduction in de novo purine synthesis by these agents. This does not appear to be a major site of action of
the derivatives which would be responsible for cell death or apoptosis.
Fig 12 The Effects of Poly(phenolic)sulfonates on L1210 Lymphoid Leukemia Thymidine
Diphosphate Kinase Activity at 50 tM Over 2 Hours
Percent
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These studies also indicated that the compounds suppressed m-RNA [II] and t-RNA [III] polymerase
activities after 60 min. Since in these assays all of the ribonucleotides were added to the reaction medium,
this inhibition with the agents appears to be due to interference with template activity of the RNA
polymerases by the compounds. Even the inhibition ofDNA polymerase ct activity by the agents may
reflect interference with the use ofthe template by the poly(phenolic)sulfonates. The polyanionic nature of
the agents may allow binding of some type to the DNA molecule since the histones are basic so that
polymerase may be having difficulty in using the template to copy a new DNA or RNA molecules.
Suramin has also been reported to block KB III nasopharynx RNA polymerase activities, E coli DNA
polymerase and RNA polymerase and Rauscher murine leukemia virus reverse transcriptase activity by
competing for the DNA template binding site on the polymerase enzyme [42]. It was postulated that
suramin binds to the basic amino acids of the enzyme perhaps via the sulfonic groups. A similar argument
could be made for the observed inhibition of polymerase activities with the poly(phenolic)sulfonates. The
poly(phenolic)sulfonates did not directly affect the DNA molecule nor does suramin [41]. L1210
lymphoid leukemiaDNA fragmentation did occur after 24 hours incubation using whole cells. Suramin has
been shown to be a DNA topoisomerase II inhibitor in PC-9 lung cancer cells and Chinese hamster
fibrosarcoma cells [41]. It is possible that poly(phenolic)sulfonates function by this method also to afford
DNA fragmentation. Evidence would suggest from the findings of the studies on poly(phenolic)sulfonates
that they have a dual mechanism of action on cancer cells. These studies have already demonstrated that
these derivatives suppress polymerase and PRPP-amido transferase activities in L1210 lymphoid leukemia
cells. These studies have demonstrated that poly(phenolic)sulfonates have characteristics of the
antineoplastic agents similar to suramin which has been used in advanced human malignant cancers that are
refractory to standard cancer chemotherapy [43]. Whereas the studies with poly(phenolic)sulfonates are in
their initial stages and certainly additional studies are warranted, and since they have demonstrated more
potency in a number of these biochemical assays than suramin, they may have potential in the future as
clinical agents to treat cancer patients.
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